Changes in QTc interval in the Citalopram for agitation in Alzheimer's Disease (CitAD) randomized trial

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Drye, Lea T ^a   Spragg, David ^b   Devanand, D P ^c   Frangakis, Constantine ^a   Marano, Christopher ^d   Meinert, Curtis L ^a   Mintzer, Jacobo E ^e   Munro, Cynthia A ^d   Pelton, Gregory ^f   Pollock, Bruce G ^g   Porsteinsson, Anton P ^h   Rabins, Peter V ^d   Rosenberg, Paul B ^d   Schneider, Lon S ⁱ   Shade, David M ^a   Weintraub, Daniel ^j   Yesavage, Jerome ^k   Lyketsos, Constantine G ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Division of Geriatric Psychiatry College of Physicians and Surgeons Columbia University ^*  (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; THIAZIDE DIURETIC AGENT; ANTIDEPRESSANT AGENT;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CARDIOVASCULAR MORTALITY; COGNITIVE DEFECT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG FEVER; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART VENTRICLE BIGEMINY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PATIENT MONITORING; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; SINGLE DRUG DOSE; CARDIOTOXICITY; COMPLICATION; DRUG EFFECTS; HEART RATE; PSYCHOMOTOR AGITATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARDIOTOXICITY; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; PSYCHOMOTOR AGITATION;

EID: 84902596807     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098426     Document Type: Article

References (30)

1. Habib AS, Gan TJ (2008) Pro: The Food and Drug Administration Black box warning on droperidol is not justified. Anesth Analg 106: 1414-1417. (Pubitemid 351571070)
2. Luo S, Michler K, Johnston P, Macfarlane PW (2004) A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 37 Suppl: 81-90. (Pubitemid 39452873)
3. Goldenberg I, Moss AJ, Zareba W (2006) QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol 17: 333-336. (Pubitemid 43344951)
4. Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89: 1363-1372. (Pubitemid 37311108)
5. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM (2003) What clinicians should know about the QT interval. JAMA 289: 2120-2127. (Pubitemid 37430214)
6. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH (2004) Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 164: 943-948. (Pubitemid 38581512)
7. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, et al. (2011) Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 22: 660-670.
8. Bergh S, Selbaek G, Engedal K (2012) Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ 344: e1566.
9. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, et al. (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343: d4551.
10. Food and Drug Administration (2011) FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm. Accessed 14 May 2014.
11. European medicines agency Homamg (2011) Pharmacovigilance Working Party (PhVWP) October 2011 plenary meeting. EMA/CHMP/PhVWP/845939/2011. Available: http://www.ema.europa.eu/docs/en-GB/document-library/Report/2011/10/WC500117061. pdf. Accessed 14 May 2014.
12. Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (2011) Report from the CMDh meeting held on 17th, 18th and 19th October 2011. Available: http://www.hma.eu/fileadmin/dateien/Human-Medicines/CMD-h-/ cmdh-pressreleases/2011-10-c.pdf. Accessed 14 May 2014.
13. Medicines and Healthcare Products Regulatory Agency (MHRA) (2011) Drug Safety Update. Vol 5 Issue 5: A1. Available: http://www.mhra.gov.uk/home/groups/ dsu/documents/publication/con137782.pdf. Accessed 14 May 2014.
14. Food and Drug Administration (2012) FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. Accessed 14 May 2014.
15. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, et al. (2013) QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 346: f288.
16. Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, et al. (2013) Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg. Am J Psychiatry.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
18. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 196-198.
19. Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, et al. (2012) Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement 8: 121-130.
20. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, et al. (2014) Effect of Citalopram on Agitation in Alzheimer's Disease - The CitAD Randomized Controlled Trial. JAMA 311: 682-691.
21. Committee for proprietary medicinal products TEAftEoMP (1997) Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. Available: http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf. Accessed 14 May 2014.
22. Food and Drug Administration (2005) Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available: http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm129357.pdf. Accessed 14 May 2014.
23. Tran H, White CM, Chow MS, Kluger J (2001) An evaluation of the impact of gender and age on QT dispersion in healthy subjects. Ann Noninvasive Electrocardiol 6: 129-133. (Pubitemid 32423399)
24. Mangoni AA, Kinirons MT, Swift CG, Jackson SH (2003) Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. Age Ageing 32: 326-331. (Pubitemid 36622239)
25. Williams ES, Thomas KL, Broderick S, Shaw LK, Velazquez EJ, et al. (2012) Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD). Am Heart J 164: 434-441.
26. Reardon M, Malik M (1996) QT interval change with age in an overtly healthy older population. Clin Cardiol 19: 949-952. (Pubitemid 26404418)
27. Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, et al. (2004) Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 44: 1352-1359. (Pubitemid 39518640)
28. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, et al. (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24: 62-69. (Pubitemid 38134167)
29. Wilton LV, Heeley EL, Pickering RM, Shakir SA (2001) Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 15: 120-126.
30. Sanofi-aventis (2009) Patient Information UROXATRAL (Alfuzosin hydrochloride extended-release tablets). Available: http://products.sanofi.us/ uroxatral/uroxatral.html. Accessed 14 May 2014.